Galapagos NV (GLPG)
Upgrades & Downgrades
Latest GLPG news
Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript
4 August 2023
Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CF...
Galapagos Stands Strong On Jyseleca Positive Clinical Data
6 May 2023
Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T ther...
Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript
24 February 2023
Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive ...
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
11 February 2023
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the st...
Galapagos shares down after announcing clinical-trial miss for Crohn's disease
9 February 2023
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints ...
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
3 January 2023
Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .
Galapagos: Slow Transformation, But Led By An Expert
31 December 2022
GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
28 December 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
8 December 2022
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima...
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Conve...
8 November 2022
Mechelen, Belgium; 8 November 2022, 22.01 CET, Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology ( ACR ) Co n vergence 2022 meeting tak...